Bausch + Lomb (BLCO) Stock Overview
Operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BLCO from our risk checks.
BLCO Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Bausch + Lomb Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.32 |
| 52 Week High | US$18.92 |
| 52 Week Low | US$12.06 |
| Beta | 0.58 |
| 1 Month Change | 3.82% |
| 3 Month Change | 6.18% |
| 1 Year Change | 31.61% |
| 3 Year Change | -18.68% |
| 5 Year Change | n/a |
| Change since IPO | -18.40% |
Recent News & Updates
BLCO: Product Pipeline And Higher 2026 Revenue Outlook Will Support Upside
For Bausch + Lomb, the analyst price target narrative has been adjusted modestly higher to $17.88 from $17.25, with analysts pointing to updated assumptions around discount rate, revenue growth, profit margin and future P/E, even as several firms recently trimmed their published targets. Analyst Commentary Recent research on Bausch + Lomb reflects a cautious but engaged analyst community, with several firms adjusting their price targets and assumptions rather than stepping away from the stock entirely.Bausch + Lomb: Even Though Growth Continues, I Don't See A Way Higher
Summary Bausch + Lomb delivers strong revenue growth and improving profitability, but the share price remains in fair value territory, warranting a 'Hold' rating. BLCO's Vision Care segment, driven by Lumify and SiHy Daily lenses, is a key growth engine with new product launches planned through 2029. Pharmaceuticals and Surgical segments show robust sales and profit gains, supported by innovative products like MIEBO, XIIDRA, and enVista Envy. Management raised 2026 revenue guidance to $5.42–$5.52 billion and EBITDA to $1.01–$1.06 billion, but valuation is not compelling versus peers. Read the full article on Seeking AlphaRecent updates
BLCO: Product Pipeline And Higher 2026 Revenue Outlook Will Support Upside
For Bausch + Lomb, the analyst price target narrative has been adjusted modestly higher to $17.88 from $17.25, with analysts pointing to updated assumptions around discount rate, revenue growth, profit margin and future P/E, even as several firms recently trimmed their published targets. Analyst Commentary Recent research on Bausch + Lomb reflects a cautious but engaged analyst community, with several firms adjusting their price targets and assumptions rather than stepping away from the stock entirely.Bausch + Lomb: Even Though Growth Continues, I Don't See A Way Higher
Summary Bausch + Lomb delivers strong revenue growth and improving profitability, but the share price remains in fair value territory, warranting a 'Hold' rating. BLCO's Vision Care segment, driven by Lumify and SiHy Daily lenses, is a key growth engine with new product launches planned through 2029. Pharmaceuticals and Surgical segments show robust sales and profit gains, supported by innovative products like MIEBO, XIIDRA, and enVista Envy. Management raised 2026 revenue guidance to $5.42–$5.52 billion and EBITDA to $1.01–$1.06 billion, but valuation is not compelling versus peers. Read the full article on Seeking Alpha
$BLCO $BHC $COO file their ARS annual financial reports and Proxy statements stating divestiture of Lens Care Vision units but no announcem
Who benefits when $BLCO $COO $BHC do not make announcements about Vision business units are divested? Not shareholders… in my opinion$BLCO $BHC $COO BHC’s ARS clearly states the divestment and discontinuation of the Vision Care Business! When will the finally announce!
$BHC divestment of $BLCO stated in the ARS financials$Cooper $Bausch + Lomb Corporation DEAL‑CERTAINTY SCORECARD (Final, Fully Integrated Version from AI and my opinion Score: 100/100 — Maxi
$BLCO & $COO Pre-Merger Research Opinion$BLCO & $COO The Silence BEFORE the AGM: A Retail Investor’s Timeline, Findings, and Opinion on SUSPICIOUS SILENCE!
$BLCO & $COO. The Silence After the AGM: A Retail Investor’s Timeline, Findings, and Opinion on an Unprecedented Governance Failure By a Retail Investor and Portfolio Manager (Opinion) --- I.Bausch + Lomb: Solid 2024 Results, But Let's Address The Elephant In The Room
Summary Bausch + Lomb reported solid Q4 and full-year 2024 earnings, with CEO Brent Saunders highlighting positives while avoiding the critical issue of Bausch Health's potential sale of its 88% stake. The company's performance review for 2024 was strong, but the future share price trajectory hinges on whether Bausch Health will divest its majority ownership. Investors are closely watching Bausch Health's decision, as it remains the key factor influencing Bausch + Lomb's market valuation and investor sentiment. Read the full article on Seeking AlphaBausch + Lomb And Bausch Health: Some Incremental Progress As We Wait For Sale News
Summary Bausch Health Companies Inc.'s debt burden remains a critical issue, with over $21 billion in long-term debt, making a sale of Bausch + Lomb Corporation a potential solution. Bausch + Lomb's Q3 performance showed revenue growth and a shift to net income, driven by new products like Xiidra and Miebo. Despite bankruptcy rumors, major institutional investors like Carl Icahn and Paulson & Co. suggest strategic moves could prevent such an outcome. Both Bausch Health and Bausch + Lomb retain “Buy” ratings due to potential debt resolution strategies and promising growth metrics, respectively. Read the full article on Seeking AlphaWith Buyout Interest, Bausch + Lomb May Still Be Worth Interest At Current Levels
Summary Bausch + Lomb stock has rebounded since January, but still offers value, especially with potential takeover interest and a solid balance sheet. BLCO shares trade at a reasonable premium to forward earnings, with a current ratio of 1.66, providing flexibility despite recent unprofitability. Risks include potential failure of takeover, economic downturns, inflation, and majority ownership by BHC, which could affect independent operations. I rate Bausch + Lomb stock a buy, given its decent deal relative to book value and potential for market recognition or acquisition premium. Read the full article on Seeking AlphaBausch + Lomb's Bet-The-Farm Xiidra Acquisition Is Looking Questionable, But Miebo Could Make The Stock A Winner
Summary Bausch + Lomb (BLCO) is a company with entrenched brands but poor recent financial performance. The company issued debt to acquire Dry Eye Disease [DED] drug Xiidra, hoping to ramp revenue to a more sensible level given their high fixed costs. The acquisition is not going well. Despite deploying substantial marketing expenses, Xiidra's revenue is mediocre and declining. However, BLCO also owns DED drug Miebo, a drug with tremendous potential. Read the full article on Seeking AlphaShareholder Returns
| BLCO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 9.8% | 3.9% | -2.6% |
| 1Y | 31.6% | -20.0% | 20.0% |
Return vs Industry: BLCO exceeded the US Medical Equipment industry which returned -20.9% over the past year.
Return vs Market: BLCO exceeded the US Market which returned 18.6% over the past year.
Price Volatility
| BLCO volatility | |
|---|---|
| BLCO Average Weekly Movement | 4.1% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BLCO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BLCO's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1853 | 13,000 | Brent Saunders | www.bausch.com |
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing.
Bausch + Lomb Corporation Fundamentals Summary
| BLCO fundamental statistics | |
|---|---|
| Market cap | US$5.67b |
| Earnings (TTM) | -US$219.00m |
| Revenue (TTM) | US$5.21b |
Is BLCO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLCO income statement (TTM) | |
|---|---|
| Revenue | US$5.21b |
| Cost of Revenue | US$2.05b |
| Gross Profit | US$3.16b |
| Other Expenses | US$3.38b |
| Earnings | -US$219.00m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.61 |
| Gross Margin | 60.62% |
| Net Profit Margin | -4.21% |
| Debt/Equity Ratio | 78.6% |
How did BLCO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/26 06:28 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bausch + Lomb Corporation is covered by 18 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Miksic | Barclays |
| Travis Steed | BofA Global Research |
| Joanne Wuensch | Citigroup Inc |